Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eremophil-1(10),11(13)-dien-12,8α-olide is a sesquiterpene lactone of the eremophilane class, primarily isolated from plants such as *Inula helenium* (Elecampane) and various *Ligularia* species. It is characterized by an α-methylene-γ-lactone moiety, which is the key pharmacophore responsible for its biological activity. This moiety acts as a Michael acceptor, forming covalent bonds with the thiol groups of cysteine residues in target proteins. Research has demonstrated that this compound possesses significant anti-inflammatory and cytotoxic properties, largely mediated through the inhibition of the NF-κB signaling pathway and the induction of apoptosis in cancer cells. While it is not an approved pharmaceutical drug, it is a constituent of herbal extracts used in traditional medicine and dietary supplements for respiratory and inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eremophil-1(10),11(13)-dien-12,8α-olide.